These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7946457)

  • 21. Enhanced cytotoxicity of 5-fluorouracil combined with [6RS]leucovorin and recombinant human interferon-alpha 2a in colon carcinoma cells.
    Houghton JA; Adkins DA; Houghton PJ
    Adv Exp Med Biol; 1993; 339():133-42; discussion 165-7. PubMed ID: 8178712
    [No Abstract]   [Full Text] [Related]  

  • 22. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
    Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon.
    Jones DV; Samaan NA; Sellin RV; Ajani JA
    Am J Med; 1992 Sep; 93(3):348-9. PubMed ID: 1524091
    [No Abstract]   [Full Text] [Related]  

  • 24. A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Kalofonos HP; Nicolaides C; Samantas E; Mylonakis N; Aravantinos G; Dimopoulos MA; Gennatas C; Kouvatseas G; Giannoulis E; Dervenis C; Basdanis G; Pavlidis N; Androulakis I; Fountzilas G;
    Am J Clin Oncol; 2002 Feb; 25(1):23-30. PubMed ID: 11823690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
    Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R
    J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer.
    Cascinu S; Fedeli A; Luzi Fedeli S; Catalano G
    Br J Cancer; 1994 Feb; 69(2):392-3. PubMed ID: 8297740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination 5-fluorouracil (FU), folinic acid (FA), and alpha-interferon 2B in advanced gastric cancer: results of a phase II trial.
    Jäger E; Bernhard H; Klein O; Wächter B; Theiss F; Dippold W; Meyer zum Büschenfelde KH; Knuth A
    Ann Oncol; 1995 Feb; 6(2):153-6. PubMed ID: 7540418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.
    Ferguson JE; Hulse P; Lorigan P; Jayson G; Scarffe JH
    Br J Cancer; 1995 Jul; 72(1):193-7. PubMed ID: 7599051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.
    Gorbonova VA; Egorov GN; Perevodchikova NI; Orel NF
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():310-4. PubMed ID: 10939991
    [No Abstract]   [Full Text] [Related]  

  • 30. 5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group.
    Kosmidis PA; Bacoyiannis C; Fountzilas G; Aravantinos G; Tsavaris N; Milathianakis C; Skarlos D
    Ann Oncol; 1997 Apr; 8(4):373-8. PubMed ID: 9209668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
    Macdonald JS; Jacobson JL; Modiano M; Moore DF; Gandara DR; Schroder LE; Chapman RA
    Invest New Drugs; 2000 Aug; 18(3):269-73. PubMed ID: 10958597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study comparing different dose levels and administration schedules of interferon-alpha 2b combined with epirubicin for prevention of recurrence in bladder cancer.
    Serretta V; Pavone C; Corselli G; Pavone-Macaluso M
    Anticancer Drugs; 1992 May; 3 Suppl 1():19-23. PubMed ID: 1611112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immuno-chemotherapy of advanced colorectal cancer with alpha-2a interferon and 5-fluorouracil. Immunopharmacological studies.
    De Filippi R; Cucchiara G; Prete SP; Marini S; Ricci F; Nunziata C; Turriziani M; Bonmassar E; Fuggetta MP; De Vecchis L
    Ann Oncol; 1991; 2(10):759-64. PubMed ID: 1801883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of cisplatin, 5-fluorouracil, and interferon-alpha-2B as first line treatment of advanced urothelial cancer.
    Bazarbashi S; Pai C; Raja MA; Rahal M; Ezzat A; Hanash K
    Urol Oncol; 2003; 21(3):185-9. PubMed ID: 12810204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
    Nichols PH; Ward U; Ramsden CW; Primrose JN
    Br J Cancer; 1994 Nov; 70(5):946-9. PubMed ID: 7947102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
    Patt YZ; Hoque A; Roh M; Ellis L; Lozano R; Carrasco CH; Charnsangavej C; Cleary K
    Am J Clin Oncol; 1999 Apr; 22(2):209-13. PubMed ID: 10199464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas.
    Scheithauer W; Pfeffel F; Kornek G; Marczell A; Wiltschke C; Funovics J
    Cancer; 1992 Oct; 70(7):1864-6. PubMed ID: 1525760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.